UNSPSC 51386011: Mabuprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02B8S6J90B, chemically known as benzeneacetamide, n-(2-hydroxyethyl)-alpha-methyl-4-(2-methylpropyl)- but generally known as mabuprofen, which bears US NIH Compound Identifier 71261. European Medicines Agency schedules Mabuprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08630MIG.

UNSPSC 51386011 Mabuprofen is a Commodity code that does not align with the recent state and local procurement activity currently tagged under it. The single recent opportunity on record—Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026—solicits naloxone and safe drug deactivation systems, not ibuprofen or other non-steroidal anti-inflammatory medications. The county is seeking 1,900 units of naloxone and 800 deactivation systems annually through competitive bidding for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida, with responses due July 26, 2023. The solicitation requires electronic bid submission through the county's e-Procurement Portal, drug-free workplace certification, E-Verify compliance, and standard insurance coverage; the contract carries a two-year initial term with one-year renewal option and potential FEMA funding.

This code shows minimal relevant recent activity for business development purposes. The single record reflects a mismatch between the code's nominal scope (ibuprofen) and the actual work being bought (opioid antagonists and drug disposal systems). State and local procurement under this UNSPSC number does not currently support a clear market signal for firms pursuing pharmaceutical or pain-relief product lines.